Synovus Financial Corp lifted its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 307,807 shares of the company’s stock after purchasing an additional 3,356 shares during the period. Johnson & Johnson accounts for approximately 0.6% of Synovus Financial Corp’s holdings, making the stock its 26th largest holding. Synovus Financial Corp’s holdings in Johnson & Johnson were worth $39,810,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Phocas Financial Corp. raised its stake in Johnson & Johnson by 999,928.6% during the 2nd quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $1,743,000 after buying an additional 125,161,066 shares during the period. Nuveen Asset Management LLC raised its stake in Johnson & Johnson by 5,447.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock worth $2,357,266,000 after buying an additional 16,619,550 shares during the period. Thoroughbred Financial Services LLC raised its stake in Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after buying an additional 3,986,071 shares during the period. Renaissance Technologies LLC raised its stake in Johnson & Johnson by 145.5% during the 2nd quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock worth $604,637,000 after buying an additional 2,572,695 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in Johnson & Johnson by 11.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after buying an additional 2,204,757 shares during the period. Institutional investors and hedge funds own 72.25% of the company’s stock.
Shares of JNJ traded up $1.57 during midday trading on Friday, hitting $133.00. The stock had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. The company has a 50 day simple moving average of $130.83 and a two-hundred day simple moving average of $134.05. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The firm has a market cap of $343.25 billion, a price-to-earnings ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is 46.45%.
Several analysts recently commented on JNJ shares. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective on the stock in a research note on Thursday, October 17th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Wells Fargo & Co dropped their price objective on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 16th. Raymond James dropped their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Finally, Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $151.64.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Gross Domestic Product (GDP)
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.